Coronary computed tomography angiography (CTA) screening for coronary artery disease (CAD) is an indispensable diagnostic tool in clinical practice because of its excellent negative predictive value and ability to exclude critical CAD. Recently, there has been increasing interest amongst clinicians and researchers in understanding the prognostic impact of coronary CTA on improving clinical outcomes and, to this end, three randomized controlled trials (RCTs): PROMISE [1], SCOT-HEART [2], and DISCHARGE [3], have been conducted to date.
